MedTrace Logo

A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma

NCT06478264 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-06-27

No results posted yet for this study

Summary

To evaluate the efficacy and safety of adebrelimab combined with chemoradiotherapy in the treatment of esophageal small cell carcinoma

Conditions

  • Esophageal Small Cell Carcinoma

Interventions

DRUG

Etoposide

100mg/m\^2, intravenous infusion for 1-3 days,21 days/cycle, 4 cycles

DRUG

Cisplatin

25mg/m\^2 ,intravenous infusion for 1-3 days ,21 days/cycle, 4 cycles

DRUG

Carboplatin

Carboplatin (AUC = 5) on 1 Day,21 days/cycle, 4 cycles ;

DRUG

Adebrelimab

1200mg adebrelimab was given intravenously on 2 day after chemotherapy,21 days/cycle, continuous use.

RADIATION

radiotherapy

Stage I-IVa , prescription dose: PTV 50Gy/25f. Stage IVb ,prescribed dose: PTV 30Gy/10f.

Sponsors & Collaborators

  • Zhangzhou Municipal Hospital

    lead OTHER

Principal Investigators

  • Weilin Chen · Zhangzhou Municipal Hospital

  • Yiming Li · First Affiliated Hospital of Xiamen University

  • Chong Deng · First Affiliated Hospital of Xiamen University

  • Shouguo Li · Zhongshan Hospital Affiliated to Xiamen University

  • Yuyi Lin · Xiamen Second Hospital

  • Qunrong Cai · The Second Affiliated Hospital of Fujian Medical University

  • Wenjie Cai · Quanzhou First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-13
Primary Completion
2026-07-13
Completion
2027-07-13

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06478264 on ClinicalTrials.gov